Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2012

01.02.2012 | Epidemiology

The association between mammographic density measures and aspirin or other NSAID use

verfasst von: Jennifer Stone, Lisa Willenberg, Carmel Apicella, Susan Treloar, John Hopper

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

There is evidence that aspirin use reduces the risk of breast cancer. Increased mammographic density is known to be associated with increased breast cancer risk. Little is known about the association between mammographic density and aspirin or other non-steroidal anti-inflammatory drug (NSAID) use, but it is possible that the association between aspirin use and breast cancer risk might be due to the effect of aspirin on mammographic density. Multiple linear regression was used to investigate the association between measures of mammographic density and the use, frequency, and duration of aspirin and other NSAIDs such as paracetamol (acetaminophen), arthritis medication, and other over-the-counter or doctor-prescribed pain medications in 3286 women from the Australian Mammographic Density Twins and Sisters Study and the Genes Behind Endometriosis Study. We found no association between either dense area or percent dense area with any of the NSAIDs examined (all P > 0.06). If aspirin is reducing the breast cancer risk in women, it is likely doing so via a different pathway other than mammographic density measures that predict breast cancer risk.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mangiapane S, Blettner M, Schlattmann P (2008) Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf 17(2):115–124PubMedCrossRef Mangiapane S, Blettner M, Schlattmann P (2008) Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf 17(2):115–124PubMedCrossRef
2.
Zurück zum Zitat Takkouche B, Regueira-Mendez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100(20):1439–1447PubMedCrossRef Takkouche B, Regueira-Mendez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100(20):1439–1447PubMedCrossRef
3.
Zurück zum Zitat Zhao YS, Zhu S, Li XW, Wang F, Hu FL, Li DD, Zhang WC, Li X (2009) Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat 117(1):141–150PubMedCrossRef Zhao YS, Zhu S, Li XW, Wang F, Hu FL, Li DD, Zhang WC, Li X (2009) Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat 117(1):141–150PubMedCrossRef
4.
Zurück zum Zitat Agrawal A, Fentiman IS (2008) NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62(3):444–449PubMedCrossRef Agrawal A, Fentiman IS (2008) NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62(3):444–449PubMedCrossRef
5.
Zurück zum Zitat Harris RE, Namboodiri KK, Farrar WB (1996) Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7(2):203–205PubMedCrossRef Harris RE, Namboodiri KK, Farrar WB (1996) Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7(2):203–205PubMedCrossRef
6.
Zurück zum Zitat McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15(6):1159–1169PubMedCrossRef McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15(6):1159–1169PubMedCrossRef
7.
Zurück zum Zitat Boyd N, Martin L, Chavez S, Gunasekara A, Salleh A, Melnichouk O, Yaffe M, Friedenreich C, Minkin S, Bronskill M (2009) Breast-tissue composition and other risk factors for breast cancer in young women: a cross-sectional study. Lancet Oncol. 10(6):569–580PubMedCrossRef Boyd N, Martin L, Chavez S, Gunasekara A, Salleh A, Melnichouk O, Yaffe M, Friedenreich C, Minkin S, Bronskill M (2009) Breast-tissue composition and other risk factors for breast cancer in young women: a cross-sectional study. Lancet Oncol. 10(6):569–580PubMedCrossRef
8.
Zurück zum Zitat Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J (2000) Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9(9):911–915PubMed Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J (2000) Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9(9):911–915PubMed
9.
Zurück zum Zitat Chow CK, Venzon D, Jones EC, Premkumar A, O’Shaughnessy J, Zujewski J (2000) Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 9(9):917–921PubMed Chow CK, Venzon D, Jones EC, Premkumar A, O’Shaughnessy J, Zujewski J (2000) Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 9(9):917–921PubMed
10.
Zurück zum Zitat Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96(8):621–628PubMedCrossRef Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96(8):621–628PubMedCrossRef
11.
Zurück zum Zitat Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95(1):30–37PubMedCrossRef Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95(1):30–37PubMedCrossRef
12.
Zurück zum Zitat Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, Giles GG, Tritchler D, Chiarelli A, Yaffe MJ, Hopper JL (2002) Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347(12):886–894PubMedCrossRef Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, Giles GG, Tritchler D, Chiarelli A, Yaffe MJ, Hopper JL (2002) Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347(12):886–894PubMedCrossRef
13.
Zurück zum Zitat Odefrey F, Stone J, Gurrin LC, Byrnes GB, Apicella C, Dite G, Cawson J, Giles GG, Treloar SA, English DR, Hopper JL, Southey MC (2010) Common genetic variants associated with breast cancer and mammographic density measures that predict disease. Cancer Res 70(4):1449–1458PubMedCrossRef Odefrey F, Stone J, Gurrin LC, Byrnes GB, Apicella C, Dite G, Cawson J, Giles GG, Treloar SA, English DR, Hopper JL, Southey MC (2010) Common genetic variants associated with breast cancer and mammographic density measures that predict disease. Cancer Res 70(4):1449–1458PubMedCrossRef
14.
Zurück zum Zitat Treloar S, Hadfield R, Montgomery G, Lambert A, Wicks J, Barlow DH, O’Connor DT, Kennedy S (2002) The International Endogene Study: a collection of families for genetic research in endometriosis. Fertil Steril 78(4):679–685PubMedCrossRef Treloar S, Hadfield R, Montgomery G, Lambert A, Wicks J, Barlow DH, O’Connor DT, Kennedy S (2002) The International Endogene Study: a collection of families for genetic research in endometriosis. Fertil Steril 78(4):679–685PubMedCrossRef
15.
Zurück zum Zitat Maskarinec G, Urano Y, Gill J, Kolonel LN (2008) Nonsteroidal anti-inflammatory drugs (NSAIDs) and mammographic density. Breast Cancer Res Treat 112(1):133–139PubMedCrossRef Maskarinec G, Urano Y, Gill J, Kolonel LN (2008) Nonsteroidal anti-inflammatory drugs (NSAIDs) and mammographic density. Breast Cancer Res Treat 112(1):133–139PubMedCrossRef
16.
Zurück zum Zitat McTiernan A, Wang CY, Sorensen B, Xiao L, Buist DS, Aiello Bowles EJ, White E, Rossing MA, Potter J, Urban N (2009) No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomarkers Prev 18(5):1524–1530PubMedCrossRef McTiernan A, Wang CY, Sorensen B, Xiao L, Buist DS, Aiello Bowles EJ, White E, Rossing MA, Potter J, Urban N (2009) No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomarkers Prev 18(5):1524–1530PubMedCrossRef
17.
Zurück zum Zitat Terry MB, Buist DS, Trentham-Dietz A, James-Todd TM, Liao Y (2008) Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(5):1088–1095PubMedCrossRef Terry MB, Buist DS, Trentham-Dietz A, James-Todd TM, Liao Y (2008) Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(5):1088–1095PubMedCrossRef
18.
Zurück zum Zitat Teter B, Fuhrman B, Barba M, Muti P (2006) Aspirin use and mammographic density as a marker of breast cancer risk in postmenopausal women, in AACR Meeting Abstracts Teter B, Fuhrman B, Barba M, Muti P (2006) Aspirin use and mammographic density as a marker of breast cancer risk in postmenopausal women, in AACR Meeting Abstracts
19.
Zurück zum Zitat Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M (2002) A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):1048–1053PubMed Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M (2002) A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):1048–1053PubMed
Metadaten
Titel
The association between mammographic density measures and aspirin or other NSAID use
verfasst von
Jennifer Stone
Lisa Willenberg
Carmel Apicella
Susan Treloar
John Hopper
Publikationsdatum
01.02.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1834-2

Weitere Artikel der Ausgabe 1/2012

Breast Cancer Research and Treatment 1/2012 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.